Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia

Authors:

Vogiatzi F, Winterberg D, Lenk L, Buchmann S, Cario G, Schrappe M, Peipp M, Richter-Pechanska P, Kulozik AE, Lentes J, Bergmann AK, Valerius T, Frielitz FS, Kellner C, Schewe DM
Journal:

Blood
Year of publication:

2019
Citation:

2019 Aug 22;134(8):713-716
doi:

10.1182/blood.2019000904
PubMed: PubMed (PMID: 31311816)
Impact factor:

–
Abstract:

–

Participating Institutes